Compare · CDT vs NVO
CDT vs NVO
Side-by-side comparison of CDT Equity Inc. (CDT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 53643.7x CDT ($3.6M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for CDT).
- NVO has more recent analyst coverage (25 ratings vs 0 for CDT).
- Company
- CDT Equity Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.6M
- $191.82B
- 1M return
- -65.45%
- -
- 1Y return
- -99.86%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 3
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CDT
- CDT Equity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
- CDT Announces Canadian Patent for AZD5904 in Male Infertility
- SEC Form NT 10-Q filed by CDT Equity Inc.
- CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Executive Officer Regan Andrew was granted 247,401 shares (SEC Form 4)
- CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
- CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
- SEC Form EFFECT filed by CDT Equity Inc.
- SEC Form 424B3 filed by CDT Equity Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care